Sudarshan Pharma Industries
SUDARSHANPHARMAINDUSTRIESLTD NSE
Sudarshan Pharma Industries
ChemicalsNSE: SUDARSHANPHARMAINDUSTRIESLTD BSE: 543828 Dyes & Pigments
Key Fundamentals
SMEDyes & PigmentsChemicalsMarket Cap
₹986 Cr
Volatility
Moderate
P/E Ratio
39.5
EBITDA
₹51.32 Cr
Return on Equity
12.13%
Debt to Equity
1.84
Book Value
₹6.82
EPS
₹4.76
52W High
₹42.79
52W Low
₹18.5
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
4- Company is expected to give good quarter
- Company has delivered good profit growth of 54.2% CAGR over last 5 years
- Promoter holding has increased by 1.54% over last quarter.
- Company's working capital requirements have reduced from 44.1 days to 17.1 days
Weaknesses
2- Stock is trading at 6.12 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
Growth Rate
Revenue Growth
38.51% higher than
3Y
Net Income Growth
45.13% lower than
3Y
Cash Flow Change
486% higher than
3Y
ROE
18.34% higher than
3Y
ROCE
32.57% lower than
3Y
EBITDA Margin (Avg.)
-13.76% lower than
3Y
Quarterly Results
| Particulars | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 99.2 | 129 | 116 | 162 | 145 | 169 | 168 | 221 | 174 |
| Expenses | 97.12 | 116 | 108 | 146 | 134 | 160 | 157 | 201 | 159 |
| Operating Profit | 2.08 | 13.05 | 7.97 | 15.93 | 11.04 | 9.21 | 10.87 | 20.2 | 15.9 |
| OPM % | 2.1% | 10.15% | 6.89% | 9.86% | 7.6% | 5.45% | 6.47% | 9.14% | 9.12% |
| Other Income | 0.98 | -0.85 | 0.51 | -0.81 | 1.21 | 1.86 | 1.52 | 4.13 | 1.22 |
| Interest | 3.94 | 3.7 | 4 | 4.4 | 5.96 | 5.94 | 6.28 | 7.53 | 8.21 |
| Depreciation | 0.67 | 0.67 | 0.63 | 0.83 | 0.88 | 0.9 | 0.91 | 1.09 | 1.41 |
| PBT | -1.55 | 7.83 | 3.85 | 9.89 | 5.41 | 4.23 | 5.2 | 15.71 | 7.5 |
| Tax % | -21.94% | 24.9% | 24.94% | 25.08% | 26.8% | 8.51% | 20.19% | 27.43% | 25.33% |
| Net Profit | -1.21 | 5.88 | 2.88 | 7.41 | 3.96 | 3.87 | 4.15 | 11.4 | 5.61 |
| EPS in Rs | -0.05 | 0.24 | 0.12 | 0.31 | 0.17 | 0.17 | 0.18 | 0.45 | 0.23 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 148 | 193 | 357 | 461 | 464 | 505 | 703 | 732 |
| Expenses | 143 | 186 | 346 | 446 | 441 | 465 | 652 | 676 |
| Operating Profit | 5 | 7 | 11 | 15 | 23 | 40 | 51 | 56 |
| OPM % | 3.2% | 3.7% | 3.1% | 3.2% | 4.9% | 8% | 7% | 8% |
| Other Income | 0 | 0 | 0 | 1 | 3 | 0 | 9 | 9 |
| Interest | 3 | 3 | 3 | 5 | 9 | 16 | 26 | 28 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 2 | 4 | 4 |
| PBT | 2 | 4 | 7 | 9 | 15 | 22 | 31 | 33 |
| Tax % | 26% | 25% | 26% | 26% | 25% | 26% | 23% | — |
| Net Profit | 1 | 3 | 5 | 7 | 11 | 16 | 23 | 25 |
| EPS in Rs | 0.13 | 0.28 | 0.54 | 0.29 | 0.48 | 0.66 | 0.97 | 1.03 |
| Div. Payout % | 0% | 0% | 0% | 10% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 24 | 24 | 24 | 24 |
| Reserves | 10 | 13 | 20 | 77 | 88 | 107 | 131 |
| Borrowings | 21 | 30 | 31 | 34 | 105 | 171 | 285 |
| Other Liabilities | 18 | 47 | 77 | 97 | 67 | 100 | 202 |
| Total Liabilities | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
| Fixed Assets | 6 | 6 | 6 | 20 | 26 | 24 | 104 |
| CWIP | 0 | 0 | 1 | 0 | 2 | 6 | 3 |
| Investments | 0 | 0 | 0 | 12 | 14 | 30 | 0 |
| Other Assets | 53 | 93 | 131 | 200 | 242 | 342 | 534 |
| Total Assets | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 1 | 3 | -4 | -29 | 6 | 35 | -2 |
| Investing | -3 | -1 | -1 | -26 | -5 | -20 | -78 |
| Financing | 0 | -1 | 4 | 66 | -12 | -14 | 79 |
| Net Cash Flow | -2 | 0 | -1 | 11 | -12 | 0 | -1 |
| Free Cash Flow | -4 | 1 | -5 | -43 | 2 | 30 | -51 |
| CFO/OP | 20 | 50 | -19 | -179 | 36 | 96 | 7 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 114 | 75 | 64 | 96 | 116 | 121 |
| Inventory Days | 46 | 49 | 51 | 63 | 74 | 117 | 129 |
| Days Payable | 40 | 91 | 80 | 78 | 49 | 76 | 111 |
| Cash Conversion Cycle | 72 | 72 | 46 | 50 | 122 | 156 | 139 |
| Working Capital Days | 35 | 29 | 27 | 54 | 62 | 53 | 17 |
| ROCE % | — | 15% | 19% | 15% | 14% | 16% | 15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sudarshan Pharma Industries insights
59 extracted metrics + investor summaries across FY20–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
8 May - Sachin Mehta resigned as CFO effective 1 May 2026, but continues as Joint Managing Director. 8 May - Sachin Mehta resigned as CFO effective 1 May 2026, but continues as Joint Managing Director.
2
Announcement under Regulation 30 (LODR)-Newspaper Publication
4 May - Newspaper advertisement for the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31-03-2026 published in (i) Mumbai Lakshdeep (Marathi) and … 4 May - Newspaper advertisement for the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31-03-2026 published in (i) Mumbai Lakshdeep (Marathi) and …
3
Announcement under Regulation 30 (LODR)-Newspaper Publication
4 May - Newspaper advertisement for the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31-03-2026 published in (i) Mumbai Lakshdeep (Marathi) and … 4 May - Newspaper advertisement for the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31-03-2026 published in (i) Mumbai Lakshdeep (Marathi) and …
4
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
1 May - Sachin Mehta resigns as CFO from 1 May 2026, continues as Joint Managing Director. 1 May - Sachin Mehta resigns as CFO from 1 May 2026, continues as Joint Managing Director.
5
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
1 May - Sachin Mehta resigns as CFO from 1 May 2026, continues as Joint Managing Director. 1 May - Sachin Mehta resigns as CFO from 1 May 2026, continues as Joint Managing Director.
Frequently Asked Questions about Sudarshan Pharma Industries
What does Sudarshan Pharma Industries Ltd do?
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]
Where is Sudarshan Pharma Industries Ltd (543828) listed?
Sudarshan Pharma Industries Ltd trades as SUDARSHANPHARMAINDUSTRIESLTD on the NSE and under code 543828 on the BSE.
Which sector does Sudarshan Pharma Industries Ltd belong to?
Sudarshan Pharma Industries Ltd is classified under the Chemicals sector, in the Dyes & Pigments industry.
What is the market capitalisation of Sudarshan Pharma Industries Ltd?
Sudarshan Pharma Industries Ltd has a market capitalisation of ₹985.9 Cr, which places it in the Small Cap band.
What is the PE ratio of Sudarshan Pharma Industries Ltd?
Sudarshan Pharma Industries Ltd trades at a PE ratio of 39.50, on earnings per share of ₹4.76, against a book value of ₹6.82 per share.
What is the 52-week high and low of Sudarshan Pharma Industries Ltd?
Over the last 52 weeks Sudarshan Pharma Industries Ltd has traded between ₹18.5 and ₹42.79.
Does Sudarshan Pharma Industries Ltd pay dividends?
Sudarshan Pharma Industries Ltd has a dividend yield of 0.76%.
What is the Return on Equity (ROE) of Sudarshan Pharma Industries Ltd?
Sudarshan Pharma Industries Ltd reported a return on equity of 12.13%. Its debt-to-equity ratio is 1.84.
Company Information
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543828.md for Sudarshan Pharma Industries Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.